Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Icu Medical Q3 2026 Results: Turns Profitable, Net Income $26.8M

For the period ending September 30, 2026, ICU Medical reported total assets of $3.94 billion and a reduction in long-term debt to $1.13 billion from $1.27 billion at year-end 2025. The company is managing risks related to a 2025 FDA Warning Letter regarding its infusion pumps and the integration of the Smiths Medical acquisition.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue560.4537.0
Gross profit234.8200.9
Profit before tax36.2-2.5
Net income26.8-3.4
EPS (diluted, $ a share)$1.07$-0.14

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+4.4%
Gross margin41.9%
Operating margin9.3%
Source

10-Q filed with the SEC, NASDAQ: ICUI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Icu Medical Inc: key numbers

Share price
$176.91Close, Nov 17
Market cap
$4.42B
Shares outstanding
25.01MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Icu Medical Inc

All →
4:28 PM ET Form 4
Insider Selling

Icu Medical Insider Elisha W. Finney Sells $316K of Stock

Elisha W. Finney sold 1,765 shares of Icu Medical Inc at $179.00 a share, worth $316K in total between Nov 12, 2026 and Nov 13, 2026. Shares held after the trade: 4,871 (-25.9%).

Value
$316K
Shares
1,765
Average price
$179.00
Holding change
-25.9%
Trade date
Nov 12, 2026 to Nov 13, 2026
4:15 PM ET 8-K
Financial Results

Icu Medical Financial Results

ICU Medical reported Q3 2026 revenue of $560.4 million, up from $537.0 million in the prior year, with GAAP net income of $26.8 million compared to a net loss in the same period last year. The company reaffirmed its full-year 2026 guidance, noting it expects results to land at the high end of its previously stated ranges.

Term
Q3 2026

“Third quarter results were ahead of our expectations for Infusion Systems and generally in line with expectations for the remainder of the business.”

Vivek Jain, ICU Medical’s Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.